These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 620537)

  • 1. Basal cell carcinoma of the skin: a biologic marker for visceral malignancy.
    Debrowsky R; Hukill PB; Lundy JL
    Conn Med; 1978 Jan; 42(1):8-10. PubMed ID: 620537
    [No Abstract]   [Full Text] [Related]  

  • 2. The incidence of skin cancer is growing rapidly.
    Nouri K
    Int J Dermatol; 2004 Aug; 43(8):622. PubMed ID: 15304193
    [No Abstract]   [Full Text] [Related]  

  • 3. Cell-mediated immune response to basal cell carcinoma.
    Raffle EJ; MacLeod TM; Hutchinson F
    Acta Derm Venereol; 1981; 61(1):66-8. PubMed ID: 6164220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunoglobulin factor reacting with components of epidermal basement membranes of patients with basal cell carcinoma].
    Kogan MG; Bukhova VP; Beletskaia LV; Berenbeĭn BA; Balashova MB
    Vestn Dermatol Venerol; 1984 Aug; (8):20-2. PubMed ID: 6485533
    [No Abstract]   [Full Text] [Related]  

  • 5. Multiple cutaneous carcinomas and lymphomas of the skin.
    Cohen C
    Arch Dermatol; 1980 Jun; 116(6):687-9. PubMed ID: 6892866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The immunological characteristics of metatypic skin cancer].
    Snarskaia ES
    Sov Med; 1991; (7):90. PubMed ID: 1948364
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immuno-allergological studies in skin cancer].
    Michailow P; Berowa N; Kutintschev M
    Hautarzt; 1966 Aug; 17(8):356-7. PubMed ID: 4965047
    [No Abstract]   [Full Text] [Related]  

  • 8. Skin site mast cell numbers correlate with rates of nodular growth, but not incidence, of basal cell carcinoma.
    Weber A; Maurer M
    Dermatology; 2005; 211(3):298-9. PubMed ID: 16205081
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.
    Fortina AB; Piaserico S; Caforio AL; Abeni D; Alaibac M; Angelini A; Iliceto S; Peserico A
    Arch Dermatol; 2004 Sep; 140(9):1079-85. PubMed ID: 15381547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T lymphocytes with Fc-IgG receptors in skin cancers.
    Vena GA; Angelini G; D'Ovidio R; Lospalluti M; Meneghini CL
    Acta Derm Venereol; 1981; 61(6):555-8. PubMed ID: 6177170
    [No Abstract]   [Full Text] [Related]  

  • 11. Decreased number of Langerhans cells in basal cell carcinoma.
    Rotsztejn H; Jesionek-Kupnicka D; Trznadel-Budźko E
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):471-3. PubMed ID: 18637859
    [No Abstract]   [Full Text] [Related]  

  • 12. The relative effects of different systemic immunosuppressives on skin cancer development in organ transplant patients.
    Durando B; Reichel J
    Dermatol Ther; 2005; 18(1):1-11. PubMed ID: 15842607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytostatic and immunologic activity of 5-mercaptouracil desoxyriboside in the management of multiple superficial basal cell epitheliomas.
    Schwartz SH; Bardos TJ; Burgess GH; Klein E
    J Med; 1970; 1(3):174-9. PubMed ID: 5280268
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antibodies induced by group A Streptococcus reacting with epidermis elements in patients with basalomas].
    Bukhova VP; Kogan MG; Berenboĭm BA; Beletskaia LV; Beliaev DL
    Vopr Onkol; 1984; 30(11):67-71. PubMed ID: 6083661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNCB reactivity in patients with skin carcinoma.
    Bleumink E; Nater JP
    Dermatologica; 1974; 148(1):44-6. PubMed ID: 4364858
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Ber-EP4 protein in recurrent metastatic basal cell carcinoma: a case report and review of the literature.
    Saladi RN; Singh F; Wei H; Lebwohl MG; Phelps RG
    Int J Dermatol; 2004 Aug; 43(8):600-3. PubMed ID: 15304188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin cancer and HLA antigens.
    Myskowski PL
    N Engl J Med; 1992 Mar; 326(11):765; author reply 766. PubMed ID: 1738388
    [No Abstract]   [Full Text] [Related]  

  • 18. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy.
    Urosevic M; Kempf W; Zagrodnik B; Panizzon R; Burg G; Dummer R
    Clin Exp Dermatol; 2005 Jul; 30(4):422-5. PubMed ID: 15953086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic basal cell carcinoma: is infiltrative/morpheaform subtype a risk factor?
    Bozikov K; Taggart I
    Eur J Dermatol; 2006; 16(6):691-2. PubMed ID: 17229614
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bound IgG, IgM, IgA and complement in the epidermis of the growth zone of skin tumors].
    Beletskaia LV; Berenbeĭn BA; Silagadze DG; Ezhov NIa
    Vestn Dermatol Venerol; 1981 Jan; (1):13-6. PubMed ID: 7210863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.